Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237286 · ClinicalTrials.gov registry record · Phase 1
Intravenous Ketamine Plus Neurocognitive Training for Depression
A Phase 1 study of Depression, sponsored by Rebecca Price.
- Completed
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
- 1
- Study location
NCT03237286: Completed Phase 1 study of Depression, sponsored by Rebecca Price.
NCT03237286 is a Phase 1 study of Depression that has completed, run by Rebecca Price. The registered enrollment target is 154 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03237286, a Phase 1 study of Depression, has completed, sponsored by Rebecca Price.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
- 1
- Study location
Study Summary
This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training. Three of the primary outcomes listed (fMRI functional connectivity; Implicit Association Test; cognitive flexibility testing) pertain to Aim 1. For Aim 2, one primary clinical outcome (MADRS, a clinician-administered measure of depression severity) pertains to the acute (30-day) phase, while the QIDS (a self-report measure of depression severity) becomes the primary clinical outcome during the 12-month naturalistic follow-up.
Primary Outcome
Clinician-rated depression (range: 0-60; higher scores = worse outcome)
Conditions Studied
Interventions
- DRUG Intravenous ketamine
- BEHAVIORAL Computer-based Cognitive Training
Study Locations (1)
Pennsylvania
- Western Psychiatric Institute and Clinic - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2022-10-18 |
| Phase | Phase 1 |
What the finished NCT03237286 record still lists
NCT03237286 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Intravenous ketamine is the first listed.
NCT03237286 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03237286 about?
NCT03237286 is a clinical study titled "Intravenous Ketamine Plus Neurocognitive Training for Depression". This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training. Three of the primary outcomes listed (fMR...
What is the current status of trial NCT03237286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2017-12-01. Estimated completion is 2022-10-18.
What conditions does trial NCT03237286 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT03237286?
The interventions under investigation include: Intravenous ketamine (DRUG), Computer-based Cognitive Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT03237286?
This trial is sponsored by Rebecca Price, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03237286 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03237286's enrollment target sits among peer trials
154 246th of 679 higher than 434 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
RECRUITING · Phase 1
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
RECRUITING · Phase 1
-
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy